Rituximab, Ifosfamide, Dexamethasone, Etoposide, and Ara-C (R-IDEA) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Rituximab, Ifosfamide, Dexamethasone, Etoposide, and Ara-C (R-IDEA) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma - R-IDEA for relapsed/refractory DLBCL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004892

Enrollment

Registered

2011-01-20

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Chemotherapy (3 or 4 cycles of R-IDEA) and High dose chemotherapy with autologous stem cell transplantation support

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with relapsed or refractory histologically-proven CD20-positive diffuse large B-cell lymphoma. Aged 18 to 65 years - ECOG performance status 0 to 2. - Previously treated with chemotherapy regimen containing anthracyclines. - Eligible for autologous stem cell transplantation. - Existence of measurable disease. - Signed written informed consent.

Exclusion criteria

Exclusion criteria: - CD20-negative diffuse large cell lymphoma - Central nervous system involvement by lymphoma. - Prior transplantation. - Contra-indication to any drug contained in the chemotherapy regimens. - Uncontrollable active infection. - Complication; uncontrollable hypertension or DM, liver cirrhosis, interstitial pneumonia, pulmonary fibrosis. - Documented infection with HIV, hepatitis B virus and Hepatitis C virus. - Pregnant women - Psychiatric illness or social situation that would preclude study compliance. - A patient who was judged as inappropriate for the trial

Design outcomes

Primary

Measure	Time frame
Mobilization-adjusted overall response rate (MARR) after 3 cycles of R-IDEA	—

Secondary

Measure	Time frame
progression-free survival, overall survival, response rate	—

Countries

Japan

Contacts

Public ContactEisei KONDO, M.D., Ph.D.

Okayama University Hospital Department of Hematology and Oncology

eisei-k@md.okayama-u.ac.jp086-235-7227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026